Last reviewed · How we verify
Tetrabenazine withdrawal
Tetrabenazine withdrawal refers to the clinical syndrome that occurs when tetrabenazine (a vesicular monoamine transporter inhibitor) is discontinued, characterized by rebound hyperkinetic movement disorders.
Tetrabenazine withdrawal refers to the clinical syndrome that occurs when tetrabenazine (a vesicular monoamine transporter inhibitor) is discontinued, characterized by rebound hyperkinetic movement disorders. Used for Management of tetrabenazine discontinuation syndrome to prevent rebound hyperkinetic movement disorders.
At a glance
| Generic name | Tetrabenazine withdrawal |
|---|---|
| Sponsor | New York Medical College |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Tetrabenazine depletes monoamines (dopamine, serotonin, norepinephrine) by inhibiting VMAT2, thereby reducing involuntary movements in hyperkinetic disorders. Upon withdrawal, sudden restoration of monoamine signaling can cause rebound worsening of chorea, akathisia, or other movement abnormalities. This is a recognized clinical phenomenon requiring careful tapering rather than abrupt discontinuation.
Approved indications
- Management of tetrabenazine discontinuation syndrome to prevent rebound hyperkinetic movement disorders
Common side effects
- Rebound chorea
- Rebound akathisia
- Worsening involuntary movements
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tetrabenazine withdrawal CI brief — competitive landscape report
- Tetrabenazine withdrawal updates RSS · CI watch RSS
- New York Medical College portfolio CI